Ran Nussbaum - 30 May 2024 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: KROS
Reported as of: 30 May 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2024, 16:15:17 UTC
Prior SEC filing: 08 Jun 2023
Next SEC filing: 11 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Keith Regnante, Attorney-in-Fact

Key filing fact

Ran Nussbaum filed Form 4 for Keros Therapeutics, Inc. (KROS) on 03 Jun 2024.

Key facts

This page summarizes Ran Nussbaum's Form 4 filing for Keros Therapeutics, Inc. (KROS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2024, 16:15.

Change

Previous filing in this sequence was filed on 08 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KROS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +10,000
Change %
Price: $0.000000
Shares after: 10,000
Date: 30 May 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $46.31
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.